Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|April 25, 2007
Skeletal metastases in non-small cell lung cancer: a retrospective studyAsuka Tsuya, Takayasu Kurata, Kenji Tamura, et al.Cancer Chemotherapy and Pharmacology|December 3, 2010
Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patientsToshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, et al.Lung Cancer (Amsterdam, Netherlands)|May 2, 2009
Long-term survivors of more than 5 years in advanced non-small cell lung cancerKyoichi Kaira, Toshiaki Takahashi, Haruyasu Murakami, et al.Japanese Journal of Clinical Oncology|September 29, 2009
Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumorsIsamu Okamoto, Toshihiko Doi, Atsushi Ohtsu, et al.International Journal of Clinical Oncology|June 18, 2010
N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastasesRieko Kaira, Haruyasu Murakami, Kyoichi Kaira, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 23, 2010
[Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer]Akihiro Tamiya, Asuka Tsuya, Yukiko Nakamura, et al.International Journal of Clinical Oncology|December 8, 2009
Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6Eriko Ayabe, Kyoichi Kaira, Toshiaki Takahashi, et al.Annals of Nuclear Medicine|September 9, 2010
Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancerKyoichi Kaira, Masahiro Endo, Koiku Asakura, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancerSatoshi Igawa, Nobuyuki Yamamoto, Shinya Ueda, et al.Pageof 7